Autism Speaks: meeting on folate metabolism and Autism spectrum disorders, March 19-20, 2009, Washington, DC.

• DOI: 10.1097/mph.0b013e31820ff78e
• Publication Date: 2011-04-01
• Authors: Barton A. Kamen; Leanne Chukoskie
• Keywords: Adult; Male; Osteosarcoma; Adolescent; Bone Neoplasms; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; 3. Good health; Necrosis; 03 medical and health sciences; 0302 clinical medicine; ROC Curve; Chemotherapy, Adjuvant; Fluorodeoxyglucose F18; Child, Preschool; Positron-Emission Tomography; Antineoplastic Combined Chemotherapy Protocols; Humans; Female; Prospective Studies; Child; Aged

The current standard for neoadjuvant chemotherapy (NACT) response evaluation in osteosarcoma is histopathologic necrosis (HN). However, it accessible only after NACT completion and may get affected by confounding factors. Thus, noninvasive surrogate such as (18)Fluorine-Fluorodeoxyglucose-positron emission tomography-computerized tomography (PET-CT) scan would be useful to individualize therapy.Thirty-one treatment naive patients evaluated prospectively PET-CT preceding 3 cycles of surgery during 2006 2008. Various anatomic metabolic parameters were compared with HN (good ≥90% HN) reference standard. Receiver operating characteristic curves generated assess the best threshold predictability.Median age was 17 years; 25 male 23 nonmetastatic. Ten cases good, whereas 21 poor histologic responders. including post-NACT (2) pre-NACT (1) uptake value (SUV)max ratio (SUV2:SUV1), SUV2, volumes (V1and V2), change V NACT, burden (MB) MB correlated HN. Two independent predictors identified stepwise multivariable analysis; if V1 ≤300 mL SUV2:SUV1 ≤0.48, observed good proportions 83%, >300 >0.48, 0%.NACT can predicted reliably early disease course (even at baseline) correlate well seems sensitive substitute evaluation. Independent have wider clinical applications further validation done.